Anzeige
Mehr »
Login
Montag, 23.12.2024 Börsentäglich über 12.000 News von 679 internationalen Medien
Die erste börsennotierte Gesellschaft, die auf das gemeinsame Wachstum von Solana, XRP und Dogecoin setzt!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3C45M | ISIN: US7473241013 | Ticker-Symbol:
NASDAQ
20.12.24
21:59 Uhr
1,695 US-Dollar
+0,155
+10,06 %
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
PYXIS ONCOLOGY INC Chart 1 Jahr
5-Tage-Chart
PYXIS ONCOLOGY INC 5-Tage-Chart

Aktuelle News zur PYXIS ONCOLOGY Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
FrPyxis Oncology's Deprioritizes Second Pipeline Asset, Analyst Applauds Move3
DoPyxis Oncology advances lead cancer drug PYX-2012
DoPyxis Oncology treibt führendes Krebsmedikament PYX-201 voran1
DoPyxis Oncology Announces Portfolio Prioritization, Focusing Resources on its Lead Clinical Program, PYX-201223- The Company will focus resources on advancing its lead asset, PYX-201 - PYX-201 is a novel first-in-concept antibody-drug conjugate (ADC) where significant RECIST responses were seen in head and...
► Artikel lesen
DoPyxis Oncology, Inc. - 8-K, Current Report-
27.11.Finanzvorstand von Pyxis Oncology erwirbt Aktien im Wert von 174.364 US-Dollar10
21.11.Pyxis Oncology's Cancer Drug Progress Stirs Analyst Concerns13
21.11.Pyxis Oncology plummets 38% on preliminary phase 1 data for cancer asset14
PYXIS ONCOLOGY Aktie jetzt für 0€ handeln
20.11.Pyxis Oncology Announces Favorable Preliminary PYX-201 Clinical Phase 1 Part 1 Data94- PYX-201 achieved a confirmed 50% ORR by RECIST 1.1 including one Complete Response and 100% Disease Control Rate in six heavily pretreated HNSCC patients, supporting differentiated mono and front-line...
► Artikel lesen
20.11.Pyxis Oncology, Inc. - 8-K, Current Report1
12.11.Pyxis Oncology, Inc. - S-8, Securities to be offered to employees in employee benefit plans-
12.11.Pyxis Oncology GAAP EPS of -$0.35 misses by $0.04-
12.11.Pyxis Oncology Provides Corporate Update and Reports Financial Results for Third Quarter 2024144- Preliminary data from the first-in-patient Phase 1 dose escalation trial of PYX-201 to be announced at upcoming virtual and in-person event in New York City on Wednesday, November 20, 2024, at 4:30...
► Artikel lesen
11.11.Pyxis Oncology to Host In-Person (NYC) and Virtual Investor Event on Wednesday, November 20, 2024, to Present Preliminary Data from the Phase 1 Dose Escalation Trial of PYX-2011
08.11.Pyxis Oncology's Cancer Drug Platform Shows Potential, Analyst Sees Over 190% Upside12
23.10.Pyxis Oncology expands equity plan by 5.5 million shares4
23.10.Pyxis Oncology, Inc. - 8-K, Current Report-
29.08.Pyxis Oncology to Participate in Two Upcoming Investor Conferences3
16.08.Pyxis Oncology maintains steady target with Buy rating from H.C. Wainwright2
15.08.Pyxis Oncology GAAP EPS of -$0.291
Seite:  Weiter >>
29 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1